Regulation of iNOS on Immune Cells and Its Role in Diseases.

Xue Q, Yan Y, Zhang R, Xiong H. · 2018

Read Regulation of iNOS on Immune Cells and Its Role in Diseases. by Xue Q, Yan Y, Zhang R, Xiong H. (2018) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc6320759.txt.

Introduction

Xue and co-authors review inducible nitric oxide synthase in immune cells and disease. The review appeared in the International Journal of Molecular Sciences. This enzyme, called iNOS, makes nitric oxide after immune triggers. Nitric oxide can kill microbes and guard the host. It can also damage healthy tissue. Macrophages, T cells, and dendritic cells all express iNOS.

The authors trace how iNOS shapes each cell type. It steers T cell differentiation and macrophage behavior. Mature dendritic cells are also affected. Nitric oxide alters key molecules in signaling paths. The review draws on lab studies in animals and humans. It closes with prospects for new research. Targeting iNOS may help several inflammatory diseases.

Catalog record

CREATORXue Q, Yan Y, Zhang R, Xiong H.
YEAR2018
COLLECTIONPAPERS
FORMATTXT
FILE SIZE48 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC6320759

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Regulation of iNOS on Immune Cells and Its Role in Diseases By Qingjie Xue, Yingchun Yan, Ruihua Zhang, Huabao Xiong Published in: International Journal of Molecular Sciences DOI: 10.3390/ijms19123805 ABSTRACT In recent years, there have been many studies on the function of nitric oxide synthase (NOS) in experimental animals and humans. This review analyzes and explores the relationship between inducible nitric oxide synthase (iNOS) and T cells, macrophages, and dendritic cell et al. differentiation using data based on laboratory research, highlighting recent NOS laboratory research. Our insights into research prospects and directions are also presented. 1. INTRODUCTION Nitric oxide (NO), which is synthesized by nitric oxide synthase (NOS), is the smallest known bioactive molecule, and can be produced by a variety of cells. NO plays an important role in neurotransmission, vascular function, host defense, and immune regulation [1]. Three NOS isoforms have been identified: neuronal nitric oxide synthase (nNOS), inducible nitric oxide synthase (iNOS), and endothelial nitric oxide synthase (eNOS) [2]. nNOS and eNOS are mainly expressed in neurons and epithelial cells, respectively, and are calcium-dependent. In contrast, calcium-independent iNOS can be produced by a variety of cells after induction by cytokines or other stimuli. NO is an important pro-inflammatory mediator with an effect on the immune system. Indeed, NO plays a dual role in the process of immunoinflammation. On the one hand, NO can kill microorganisms and has a protective effect on the body, helping to fight against various viruses, such as herpes simplex virus (HSV). On the other hand, NO can damage normal tissue cells to generate pathogenic effects, and is widely involved in the development of various diseases, such as Borna disease [3]. According to existing research, macrophages and other effector cells, including neutrophils, monocytes, and endothelial cells, are the main effector cells involved in the antimicrobial effects of NO [4,5]. Studies have shown that iNOS is expressed by T cells, macrophages, and mature dendritic cells (mDCs), and regulates the differentiation and function of immune cells via nitration of key molecules involved in transcriptional or signaling pathways [6,7,8]. This article reviews and discusses recent experimental research. 2. INOS AND T CELL DIFFERENTIATION By inactivating and destroying infectious agents, NO is an important pro-inflammatory cytotoxic agent that protects the host against various pathogens [6,7,8,9]. Interestingly, NO also plays a key inhibitory role in immunity [10,11,12]. Previously, we and other research groups reported that NO inhibits the production of IL-12 in dendritic cells and macrophages [13], which suggests that NO can control the production of Th1 immune responses by modulating IL-12 expression. It has also been reported that enhanced iNOS expression in T cells regulates the differentiation of Th17 cells. For example, in inflammatory bowel disease (IBD), iNOS expressed by T cells negatively regulates Th17 differentiation (Figure 1A) through nitration of orphan receptors γt associated with retinoic acid (RORγt) [14]. Our group has shown that iNOS−/− mice exhibit enhanced Th17 cell differentiation without significant effects on Th1 or Th2 cells (Figure 1A). Expression of iNOS was found to be induced in activated CD4+ T cells, and the percentage of IL-17 produced by CD4+ T cells in WT (wide type) mice was significantly increased by treatment with the iNOS-selective inhibitor N6-(1-iminoethyl)-1-lysine dihydrochloride (L-NIL). In addition, NO donors, such as S-nitroso-N-acetylpenicillamine (SNAP), dose-dependently inhibit IL-17 production in cultured T cells from WT and iNOS−/− mice [15]. Furthermore, nitration of the tyrosine residue of RORγt results in inhibition of RORγt-mediated IL-17 promoter activation, and naïve T cells obtained from iNOS-deficient mice induce more severe colitis in Rag−/− mice than do normal control T cells. These results indicate that NO plays an important inhibitory role in controlling Th17 differentiation and highlight the importance of T cell-derived iNOS in mediating Th17-dependent immune responses. Th17 cells comprise a newer subset of the T helper cell family, and play a key role in the pathogenesis of autoimmune and inflammatory diseases [15,16]. Therefore, understanding the intrinsic inhibition program of Th17 cells will help in elucidating the mechanisms underlying the Th17 immune response and the development of inflammatory diseases, including IBD, multiple sclerosis (MS), and rheumatoid arthritis (RA). Mice carrying T cells from iNOS−/− mice show a higher percentage of IL-17 produced by CD4+ T cells than do mice harboring T cells from WT mice [16]. These results indicate that iNOS derived from activated T cells selectively regulates T cell differentiation. Studies have also shown that NO can play a dual role in regulating immune responses [17]. In fact, NO produced by iNOS in macrophages and other innate immune cells is pro-inflammatory, and an essential component of the host immune response against various pathogens, including bacteria, parasites, and viruses [18]. Nonetheless, there is increasing evidence that NO can promote immunosuppression. We and other research groups previously reported a significant increase in IL-12 mRNA and protein expression in iNOS KO mice (control), suggesting that NO may inhibit IL-12-mediated Th1 immune responses [13,19]. Huang et al. [20] suggested that the enhanced Th1 immune response in iNOS knockout mice (iNOS−/−) after infection with Leishmania major is caused by an increase in IL-12 production by macrophages. In a previous study, we clearly demonstrated that iNOS expressed by activated CD4+ T cells negatively regulates the differentiation of Th17 cells, consistent with findings that the NO donors NOC-18 and S-nitrosoglutathione (SNO) inhibit Th17 cell differentiation [11,21]. Therefore, the overall results support the view that by selectively inhibiting Th17 cell development, NO from iNOS controls T cell differentiation in activated T cells. The importance of RORγt in the development of Th17 cells has been well documented in mice. For instance, RORγt−/− mice fail to form lymph nodes or Peyer’s plaques, and their Th17 cells were severely impaired, suggesting that RORγt is the major transcription factor in Th17 cell differentiation [22]. Interestingly, RORγt expression in iNOS−/− mouse CD4+ T cells cultured under Th17 conditions was comparable to that of CD4+T cells from WT mice, suggesting that enhanced Th17 cell differentiation is not a result of increased RORγt protein levels. In contrast, we found that the NOS donor SNAP inhibited RORγt-mediated IL-17 promoter activation in a dose-dependent manner, which indicates that NO can control RORγt activity during IL-17 gene transcription [13,15]. NO directly affects the activity of many proteins via tyrosine nitration [13]. Nitration of tyrosine residues in RORγt significantly impairs the binding of RORγt to the promoter region of the IL-17 gene, inhibiting IL-17 transcription. Studies of RORγt mutants have shown that the tyrosine residue between amino acids 169 and 491 is a possible target for NO nitration [15]. Combining information based on the crystal structure of human RORγt and its ligand-binding domain using the antagonist digoxin, we found that several tyrosine residues are present in this region, with Tyr369 and Tyr382 located near the binding site. Thus, tyrosine nitration can greatly affect RORγt ligand formation and binding activity. Moreover, mutation experiments have demonstrated that Tyr346 and Tyr359 of mouse RORγt, corresponding to Tyr369 and Tyr382 of human RORγt, play a key role in RORγt transcriptional activation. Therefore, Tyr346 and Tyr359 may be targets of NO in RORγt transcriptional modulation. Recently, Niedbala et al. [11] reported that the NO donor NOC-18 inhibits AHR protein expression in Th17 cells, and concluded that NO suppresses Th17 cell development

Read the complete text